Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2019

06.11.2019 | short review

Current trends in small cell lung cancer management—ASCO 2019 update

verfasst von: MD, PhD Mircea Dediu

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

During the last 30 years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the standard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the most important abstracts presented at ASCO 2019 along with their potential impact for current clinical practice.
Literatur
1.
Zurück zum Zitat Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84. CrossRef Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84. CrossRef
2.
Zurück zum Zitat Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer:a phase 3 randomized controlled trial. Lancet. 2015;385(9962):36–42. CrossRef Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small cell lung cancer:a phase 3 randomized controlled trial. Lancet. 2015;385(9962):36–42. CrossRef
3.
Zurück zum Zitat Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first line therapy for small cell lung cancer. J Clin Oncol. 1985;3(11):1471–7. CrossRef Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first line therapy for small cell lung cancer. J Clin Oncol. 1985;3(11):1471–7. CrossRef
5.
Zurück zum Zitat Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. CrossRef Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. CrossRef
6.
Zurück zum Zitat Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15(5):2090–6. CrossRef Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15(5):2090–6. CrossRef
7.
Zurück zum Zitat von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67. CrossRef von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67. CrossRef
8.
Zurück zum Zitat von Pawel J, Jotte R, Spigel DR, O’Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–9. CrossRef von Pawel J, Jotte R, Spigel DR, O’Brien ME, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–9. CrossRef
10.
Zurück zum Zitat Paz-Ares L, Perez J, Besse B, Moreno V, Lopez R, Sala, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. J Clin Oncol. 2019;37(suppl):abstr 8506. Paz-Ares L, Perez J, Besse B, Moreno V, Lopez R, Sala, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. J Clin Oncol. 2019;37(suppl):abstr 8506.
11.
Zurück zum Zitat George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7536):47–53. CrossRef George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7536):47–53. CrossRef
12.
Zurück zum Zitat Hart L, Andric Z, Hussein M, Ferrarotto R, Beck T, Subramanian J, et al. Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. J Clin Oncol. 2019;37(suppl):abstr 8505. Hart L, Andric Z, Hussein M, Ferrarotto R, Beck T, Subramanian J, et al. Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. J Clin Oncol. 2019;37(suppl):abstr 8505.
13.
Zurück zum Zitat Dragnev K, Owonikoko T, Csoszi T, Maglakelidze M, Bec JT, Gomez, et al. Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy. Ann Oncol. 2018;29(suppl_8):viii596–viii602. CrossRef Dragnev K, Owonikoko T, Csoszi T, Maglakelidze M, Bec JT, Gomez, et al. Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy. Ann Oncol. 2018;29(suppl_8):viii596–viii602. CrossRef
14.
Zurück zum Zitat Owonikoko T, Higgins K, Chen Z, Zhang C, Pillai R, Steuer CE, et al. A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). J Clin Oncol. 2019;37(suppl):abstr 8515. Owonikoko T, Higgins K, Chen Z, Zhang C, Pillai R, Steuer CE, et al. A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). J Clin Oncol. 2019;37(suppl):abstr 8515.
15.
Zurück zum Zitat Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel J, et al. Ph1/2 study of Rova‑T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. J Clin Oncol. 2019;37(suppl):abstr 8516. Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel J, et al. Ph1/2 study of Rova‑T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. J Clin Oncol. 2019;37(suppl):abstr 8516.
16.
Zurück zum Zitat Carbone D, Morgensztern D, Le Moulec S, Santana-Davila R, Ready N, Hann C, et al. Efficacy and safety of rovalpituzumab tesirine (Rova-TTM) in patients with DLL3-expressing, ≥3rd line small cell lung cancer: results from the phase 2 TRINITY study. J Clin Oncol. 2018;36(suppl):abstr 8507. CrossRef Carbone D, Morgensztern D, Le Moulec S, Santana-Davila R, Ready N, Hann C, et al. Efficacy and safety of rovalpituzumab tesirine (Rova-TTM) in patients with DLL3-expressing, ≥3rd line small cell lung cancer: results from the phase 2 TRINITY study. J Clin Oncol. 2018;36(suppl):abstr 8507. CrossRef
17.
Zurück zum Zitat Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, et al. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. Oncotarget. 2017;8(4):5992–6002. CrossRef Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, et al. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. Oncotarget. 2017;8(4):5992–6002. CrossRef
18.
Zurück zum Zitat Park S, Shim J, Jung H, Sun JM, Lee SH, Park WY, et al. Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. J Clin Oncol. 2019;37(suppl):abstr 8514. Park S, Shim J, Jung H, Sun JM, Lee SH, Park WY, et al. Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. J Clin Oncol. 2019;37(suppl):abstr 8514.
19.
Zurück zum Zitat Owonikoko TK, Kim HR, Govindan R, Ready N, M. Reck M, Peters S, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Presented at: 2019 European Lung Cancer Congress; April 11 to 13, 2019; Geneva, Switzerland. Abstract LBA1. Owonikoko TK, Kim HR, Govindan R, Ready N, M. Reck M, Peters S, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Presented at: 2019 European Lung Cancer Congress; April 11 to 13, 2019; Geneva, Switzerland. Abstract LBA1.
20.
Zurück zum Zitat Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032. J Thorac Oncol. 2019;14(2):237–44. CrossRef Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032. J Thorac Oncol. 2019;14(2):237–44. CrossRef
21.
Zurück zum Zitat Phase 3 Trial of Rova‑T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted. AbbVie. Published December 5, 2018. https://​bit.​ly/​2KZcyVl. Accessed December 6, 2018. Phase 3 Trial of Rova‑T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted. AbbVie. Published December 5, 2018. https://​bit.​ly/​2KZcyVl. Accessed December 6, 2018.
Metadaten
Titel
Current trends in small cell lung cancer management—ASCO 2019 update
verfasst von
MD, PhD Mircea Dediu
Publikationsdatum
06.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00539-2

Weitere Artikel der Ausgabe 4/2019

memo - Magazine of European Medical Oncology 4/2019 Zur Ausgabe